The reason for increased UTI risk in SGLT2I users is attributed to glycosuria, which leads to poor neutrophil mobilization in the urinary tract along with the delayed release of interleukin-6 and interleukin-1b [18]. Here, IL6 is linked to bacterial urinary tract infection.